CD274 and small cell lung carcinoma: For extensive-stage SCLC (ES-SCLC), first-line therapy remains platinum-etoposide combined with a PD-L1 inhibitor such as atezolizumab or durvalumab, which improves overall survival by roughly two to three months compared with chemotherapy alone [2,3].